Kevin Frost, CEO amFAR
Download Audio (MP3) Download Video (MOV)
Kevin Frost, CEO of amFAR, sat down with aids2031 in San Francisco to talk about the present state of the struggle against AIDS, the importance of prevention in combating the epidemic and envisioning a world without AIDS.
Prior to joining amfAR, Mr. Frost spent four years at the New York University Medical Center where he worked primarily on clinical research studies of cytomegalovirus retinitis in people with HIV/AIDS. Subsequently, he served for a year as the inpatient care coordinator of the AIDS program at New York City’s Bellevue Hospital.
Beginning in 1998, Mr. Frost worked extensively in Asia where he facilitated the development of TREAT Asia, a network of more than 50 hospitals, community clinics, NGOs, and health care facilities, working together with civil society in seventeen countries in order to build the capacity necessary for scaling up treatment efforts in the region. Mr. Frost also served as a member of the international advisory committee for the XIV International AIDS Conference in Barcelona, Spain and was a member of the Scientific Committee for the XVI International AIDS Conference in Toronto, Canada in August of 2006.
Mr. Frost has served on the advisory panels for three U.S. Food and Drug Administration hearings on (1) a new drug application for Chiron Corporation’s ganciclovir implant, (2) a new drug application for Gilead’s cidofovir, and (3) a review of the application for fomivirsen sodium. He has published in the Lancet, Journal of Clinical Epidemiology, Journal of AIDS (JAIDS), Journal of Infectious Diseases, and The AIDS Reader.